Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
8.360
+0.080 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about REGENXBIO Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study
↗
March 11, 2026
The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.
Via
Stocktwits
Topics
Death
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
REGENXBIO INC (NASDAQ:RGNX) Stock Plunges 15% After Q4 Earnings Miss
↗
March 05, 2026
Via
Chartmill
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks?
↗
February 27, 2026
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.
Via
Stocktwits
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction
↗
January 28, 2026
Via
Stocktwits
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Analyst Expectations For Regenxbio's Future
↗
August 19, 2025
Via
Benzinga
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy
↗
February 26, 2026
Following the comments, shares of both Regenxbio and uniQure traded in the red.
Via
Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy
↗
February 20, 2026
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
February 16, 2026
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...
Via
MarketMinute
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Biotech Beat Nvidia in 2025. Can It Do It Again?
↗
February 11, 2026
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
Via
The Motley Fool
Topics
Artificial Intelligence
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street
↗
February 09, 2026
Clear Street pointed to strength in RGX-202 data for Duchenne and early results from Sura-Vec in wet AMD.
Via
Stocktwits
Why Did RGNX Shares Plummet 19% After-Hours Today?
↗
February 09, 2026
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.
Via
Stocktwits
Monday's after hours session: top gainers and losers
↗
February 09, 2026
Via
Chartmill
Gapping stocks in Wednesday's session
↗
January 28, 2026
Via
Chartmill
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy?
↗
January 28, 2026
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.
Via
Stocktwits
Top movers in Wednesday's pre-market session
↗
January 28, 2026
Via
Chartmill
My Top 4 Stocks to Buy in Early 2026
↗
January 22, 2026
These stocks offer impressive long-term upside with downside protection.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...
Via
MarketMinute
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress
↗
November 06, 2025
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026.
Via
Chartmill
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
↗
October 07, 2025
Via
Benzinga
7 Analysts Assess Regenxbio: What You Need To Know
↗
October 07, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts
↗
September 08, 2025
Via
Benzinga
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
↗
September 05, 2025
Regenxbio reported sustained biomarker reduction and positive neurodevelopmental outcomes in the pivotal CAMPSIITE trial of RGX-121 for MPS II.
Via
Benzinga
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
↗
August 19, 2025
FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients.
Via
Benzinga
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls
↗
August 07, 2025
REGENXBIO Q2 2025 earnings miss estimates with $21.36M revenue and -$1.38 EPS. Stock drops 2.3% pre-market amid clinical pipeline updates for DMD and diabetic retinopathy therapies.
Via
Chartmill
Topics
Earnings
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
August 27, 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Retirement
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts
↗
June 09, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
